Exenatide Acetate Salt API CAS 141732-76-5 | Peptide Manufacturer
Exenatide Acetate Salt API CAS 141732-76-5 | Peptide Manufacturer
Exenatide Acetate API,CAS 141732-76-5,Exenatide Acetate,GLP-1 receptor agonist,Custom Peptide Synthesis,Bulk Peptide Supplier,cGMP Peptide Manufacturing
Source high-purity Exenatide Acetate peptide API (CAS 141732-76-5) directly from cGMP manufacturer. Purity ≥98.0% by HPLC. Flexible packaging from mg to bulk kg for metabolic formulation R&D.
Send Inquiry
Description
cGMP STANDARD PHARMACEUTICAL PEPTIDE SUPPLIER
Exenatide Acetate Salt
CAS No.: 141732-76-5
Purity (HPLC)≥ 98.0%
Molecular FormulaC184H282N50O60S · xCH3COOH
Molecular Weight4304.65 Da (Acetate Salt)
Peptide Content / AcetateCustom / Controlled
💡 Quick Connection Notice: If your email link doesn't open, please directly send inquiries to: betty@pharma-sunrise.com
Scientific Overview & Supply Chain Reliability
We specialize in supplying high-purity Exenatide Acetate active pharmaceutical ingredient (API) powder via advanced solid-phase peptide synthesis (SPPS) platforms. Meticulously monitored under standardized cGMP pharmaceutical quality control procedures, each manufactured batch undergoes complete structural verification and rigorous HPLC testing to ensure a stable purity level of 98% and above.
We recognize the critical importance of supply chain flexibility and rigorous batch reproducibility in innovative drug development. Consequently, we offer comprehensive packaging architecture across all lifecycle stages – from milligram-scale process exploration and pre-clinical assay evaluations to large-scale bulk kilogram commercial production, securely accelerating your targeted metabolic and diabetes therapeutics projects.
Pharmacological Action & Mechanism Profile
Mechanism of Action (MoA)
Exenatide functions as a potent Glucagon-like Peptide-1 (GLP-1) receptor agonist. It targets metabolic pathways by mimicking the endogenous incretin hormone GLP-1, binding specifically to and activating the GLP-1 receptors on targeted cell membranes. This process triggers canonical intracellular signaling cascade pathways, including cyclic adenosine monophosphate (cAMP) accumulation. Crucially, compared to native GLP-1, exenatide exhibits significant structural resistance to enzymatic degradation by dipeptidyl ppetidase-4 (DPP-4), enabling an extended half-life in vivo and sustainable long-term blood glucose modulation.
Core Pharmacological Axes
• Glucose-dependent Insulin Modulation: Stimulates insulin release from pancreatic beta cells exclusively under elevated blood glucose conditions, substantially minimizing hypoglycemia profiles.
• Glucagon Suppression: Restrains the hyper-secretion of glucagon from pancreatic alpha cells, lowering overall hepatic glucose output.
• Delayed Gastric Emptying: Prolongs gastric food retention times, moderating intestinal nutrient absorption rates to blunt postprandial glucose spikes and elevate satiety lines.
• Appetite Regulation: Acts target-specifically on cerebral feeding centers to aid in appetite and food intake reduction models.
API Formulation Objectives & Clinical Reference Documentation
When successfully processed into finished pharmaceutical delivery systems, this active ingredient yields highly reproducible clinical references:
✔ Effective Glycemic Reduction: Potently mitigates both fasting and postprandial blood glucose markers in type 2 diabetes therapeutic assays.
✔ Sustainable HbA1c Control: Provides a stable, long-term lowering and maintenance of glycated hemoglobin (HbA1c) baselines.
✔ Beneficial Weight Management: Assists downstream weight maintenance models via biological satiety enhancement and delayed nutrient transit.
✔ Islet Cell Protection: Demonstrates a clear protective index on beta-cells by systematically alleviating glucotoxicity and lipotoxicity parameters.
Product Applications & Clinical Scheme Development
Formulation Manufacturing
Core active component for developing commercial injectable devices, including pre-filled pen injectors for type 2 diabetes management.
Novel Delivery Systems
Deployed as a high-grade raw material in innovative drug delivery research, focusing on long-acting biodegradable microspheres and oral peptide technologies.
Combination Therapies
Perfectly suited for pharmaceutical evaluation in fixed-dose combination formulations paired with basal insulin or other standard anti-diabetic agents.
Technical Specifications & Logistics
| Product Identity | Exenatide Acetate (Synthetic Polypeptide API) |
|---|---|
| Characteristics / Appearance | White to off-white lyophilized hygroscopic powder |
| Test Method & Purity | HPLC Analysis; Assay ≥ 98.0% |
| Flexible Packaging Options | • R&D Tiers: 10–100 mg per protective glass vial • Scaling Tiers: 1–5 kg per advanced aluminum vacuum foil bag • Commercial Bulk: 25 kg inside heavy-duty industrial fiber drums *Fully customizable packaging specifications are available upon request. |
| Storage Conditions | Keep tightly sealed. Store frozen at -20°C ± 5°C. Protect strictly from light and moisture ingress. Avoid repeated freeze-thaw cycles. |
| Shelf Life | 36 months under recommended sealed, low-temperature storage conditions. |
Frequently Asked Questions (Regulatory & Procurement)
Can you provide the complete raw analytical data profiles with the Exenatide API?
Yes. Every single batch of Exenatide Acetate API is released with a comprehensive Certificate of Analysis (COA). We gladly supply underlying raw analytical data sheets, including clear HPLC chromatograms (confirming purity ≥98.0%) and Mass Spectrometry (MS) verification to guarantee absolute sequence identity.
Are custom packaging options available for novel microsphere or oral delivery R&D?
Absolutely. We specialize in accommodating the full pipeline of pharmaceutical innovation. Beyond our mass commercial bulk kilogram lots, we support pilot-scale and laboratory-scale developers with specific packaging options ranging from milligram to gram vials to minimize raw material waste during process exploration.
How is product stability secured under sub-zero transport mandates?
To preserve the precise hygroscopic lyophilized matrix and biological activity of the peptide, all international air freight relies on fully validated cold-chain logistics. The active raw material is vacuum-packed inside moisture-proof foil barriers and transferred via temperature-monitored shipping compartments containing active data-logging hardware.
Is this peptide API suitable for direct human clinical use or injection?
No. As clearly detailed in our regulatory disclaimer, this product is an Active Pharmaceutical Ingredient (API) intended strictly for industrial process development, formulation manufacturing, and scientific research under professional oversight. It cannot be sold or distributed for direct human clinical medication, food additives, or cosmetic applications.
Shaanxi Sunrise Pharmaceutical Co., Ltd.
Senior Independent Site Operations Specialist: Betty
📧 Email: betty@pharma-sunrise.com|💬 WhatsApp: +86 18092760627